Breast cancer research and treatment · 2026
Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kroll Matthew R, Schroeder Mary C, Neuner Joan M, Viyyuri Brahmendra R, Ravindra Aditya, McDougall Dana, Chapman Cole G, Fleege Nicole M G, Chrischilles Elizabeth A, Song Xing, Phadke Sneha
Аннотация
PURPOSE: Triple‑negative breast cancer (TNBC) is an aggressive disease with poor survival outcomes. With the integration of immunotherapy, the optimal neoadjuvant chemotherapy backbone remains poorly defined. We examined real-world treatment patterns and response rates among patients receiving a carboplatin-based regimen, with or without anthracyclines.
METHODS: In this retrospective cohort study, women diagnosed 2012-2024 with stage I-III TNBC who received neoadjuvant carboplatin plus taxane (CbT) or CbT with anthracyclines (AC-CbT) were identified from electronic health records data from 10 sites within the Greater Plains Collaborative network. Registry-recorded physician assessment of pathologic complete response (pCR) was the primary outcome. Multivariable logistic regression evaluated whether adding anthracyclines to carboplatin-based treatment was associated with pCR.
RESULTS: Among 878 patients with TNBC, 41.2% received CbT and 58.8% received AC-CbT. Overall, 46% received pembrolizumab, 11.7% in the CbT group and 66.3% in the AC-CbT group. On univariate analysis, pCR rates did not differ between the CbT and AC-CbT groups (47.2% vs. 51.9%, OR = 1.21, 95%CI 0.92-1.58), among patients who underwent surgery. In multivariate adjusted analyses, AC-CbT was not associated with higher odds of pCR (aOR = 1.05, 95%CI 0.69-1.59), among patients who underwent surgery. Other patient characteristics associated with pCR included pembrolizumab use, higher-grade disease, lower stage, and age at diagnosis (40-49 versus 60+). Use of carboplatin-containing regimens increased substantially over time.
CONCLUSION: In this real-world cohort, addition of anthracycline to carboplatin-containing regimen was not associated with an improvement in pCR rates. These findings suggest clinical equipoise regarding anthracycline omission in early-stage TNBC, to be validated in prospective trials. Additional work evaluating adherence, toxicity, and long-term outcomes is needed.
METHODS: In this retrospective cohort study, women diagnosed 2012-2024 with stage I-III TNBC who received neoadjuvant carboplatin plus taxane (CbT) or CbT with anthracyclines (AC-CbT) were identified from electronic health records data from 10 sites within the Greater Plains Collaborative network. Registry-recorded physician assessment of pathologic complete response (pCR) was the primary outcome. Multivariable logistic regression evaluated whether adding anthracyclines to carboplatin-based treatment was associated with pCR.
RESULTS: Among 878 patients with TNBC, 41.2% received CbT and 58.8% received AC-CbT. Overall, 46% received pembrolizumab, 11.7% in the CbT group and 66.3% in the AC-CbT group. On univariate analysis, pCR rates did not differ between the CbT and AC-CbT groups (47.2% vs. 51.9%, OR = 1.21, 95%CI 0.92-1.58), among patients who underwent surgery. In multivariate adjusted analyses, AC-CbT was not associated with higher odds of pCR (aOR = 1.05, 95%CI 0.69-1.59), among patients who underwent surgery. Other patient characteristics associated with pCR included pembrolizumab use, higher-grade disease, lower stage, and age at diagnosis (40-49 versus 60+). Use of carboplatin-containing regimens increased substantially over time.
CONCLUSION: In this real-world cohort, addition of anthracycline to carboplatin-containing regimen was not associated with an improvement in pCR rates. These findings suggest clinical equipoise regarding anthracycline omission in early-stage TNBC, to be validated in prospective trials. Additional work evaluating adherence, toxicity, and long-term outcomes is needed.